Description

SUHAGRA 100 MG (1X10)

Indications

SUHAGRA 100 MG is primarily indicated for the treatment of erectile dysfunction (ED) in adult men. Erectile dysfunction is a condition characterized by the inability to achieve or maintain an erection sufficient for satisfactory sexual performance. SUHAGRA contains the active ingredient Sildenafil Citrate, which is a phosphodiesterase type 5 (PDE5) inhibitor. This medication is prescribed when the erectile dysfunction is of a physiological or psychological origin, and it is essential for patients to consult a healthcare professional for a proper diagnosis before starting treatment.

Mechanism of Action

The active ingredient in SUHAGRA, Sildenafil Citrate, works by inhibiting the enzyme phosphodiesterase type 5 (PDE5). This enzyme is responsible for the breakdown of cyclic guanosine monophosphate (cGMP), a molecule that plays a crucial role in the physiological process of erection. When sexual stimulation occurs, nitric oxide is released in the corpus cavernosum, leading to increased levels of cGMP. By inhibiting PDE5, SUHAGRA increases cGMP levels, resulting in enhanced blood flow to the penis and facilitating an erection in response to sexual arousal. It is important to note that sexual stimulation is necessary for the drug to exert its effects.

Pharmacological Properties

SUHAGRA is rapidly absorbed after oral administration, with peak plasma concentrations typically reached within 30 to 120 minutes. The bioavailability of Sildenafil is approximately 40%, and its effects can last for up to four hours, although individual responses may vary. The drug is metabolized primarily in the liver by cytochrome P450 enzymes, particularly CYP3A4, and is excreted mainly through the feces and urine. The pharmacokinetics of SUHAGRA can be influenced by various factors, including age, liver function, and concurrent medications.

Contraindications

SUHAGRA is contraindicated in patients who are hypersensitive to Sildenafil or any of the excipients in the formulation. It should not be used in conjunction with nitrates or nitric oxide donors, as this can lead to severe hypotension. Patients with a history of cardiovascular disease, particularly those who have experienced a recent heart attack or stroke, should avoid using this medication unless specifically advised by a healthcare provider. Additionally, SUHAGRA is contraindicated in individuals with severe hepatic impairment or those who are on medications that are strong inhibitors of CYP3A4.

Side Effects

Common side effects associated with SUHAGRA include headache, flushing, dyspepsia, nasal congestion, and dizziness. These side effects are generally mild to moderate and tend to resolve on their own. However, some patients may experience more serious side effects, including visual disturbances, sudden hearing loss, or priapism (a prolonged and painful erection). Patients should seek immediate medical attention if they experience any severe or persistent side effects. It is important to discuss any pre-existing conditions or concerns with a healthcare provider prior to starting treatment.

Dosage and Administration

The recommended starting dose of SUHAGRA for most patients is 50 MG, taken approximately one hour before sexual activity. Depending on efficacy and tolerability, the dose may be adjusted to a maximum of 100 MG or reduced to 25 MG. It is important not to exceed one dose in a 24-hour period. SUHAGRA can be taken with or without food; however, high-fat meals may delay the onset of action. Patients are advised to follow their healthcare provider’s instructions regarding dosage and administration for optimal results.

Interactions

SUHAGRA may interact with various medications, which can affect its efficacy and safety. Concomitant use of nitrates, such as nitroglycerin, can lead to a dangerous drop in blood pressure. Other medications that may interact with SUHAGRA include alpha-blockers, antihypertensives, and certain antifungal and antiviral agents that inhibit CYP3A4. It is crucial for patients to inform their healthcare provider of all medications they are currently taking, including over-the-counter drugs and herbal supplements, to avoid potential interactions.

Precautions

Before starting treatment with SUHAGRA, patients should undergo a thorough medical evaluation to assess their cardiovascular health and overall suitability for the medication. Caution is advised in patients with anatomical deformities of the penis, such as Peyronie’s disease, or those with conditions that may predispose them to priapism. Additionally, elderly patients and those with underlying health conditions may require closer monitoring during treatment. Regular follow-up appointments with a healthcare provider are recommended to evaluate the effectiveness of the medication and to make any necessary adjustments to the treatment plan.

Clinical Studies

Numerous clinical studies have demonstrated the efficacy and safety of Sildenafil Citrate in treating erectile dysfunction. In randomized, placebo-controlled trials, patients treated with SUHAGRA reported significant improvements in erectile function and overall satisfaction compared to those receiving placebo. The studies have shown that the medication is effective across various etiologies of erectile dysfunction, including those related to diabetes, hypertension, and psychological factors. Long-term studies have also indicated that SUHAGRA maintains its efficacy over time, with a favorable safety profile.

Conclusion

SUHAGRA 100 MG is a well-established treatment for erectile dysfunction, offering significant benefits for men experiencing this condition. By enhancing blood flow to the penis and facilitating erections, it can improve sexual performance and quality of life. However, it is essential for patients to use this medication responsibly, under the guidance of a healthcare professional, to ensure safety and effectiveness. Regular follow-ups and open communication with healthcare providers are crucial for managing erectile dysfunction effectively and addressing any concerns that may arise during treatment.